Hepatitis A Community
About This Community:

This community is an un-mediated, patient-to-patient community for questions and support regarding Hepatitis A. Topics in this forum include but are not limited to, Causes, Diagnosis, Family and Relationships, Living With Hep A, Research Updates, Treatment, Success Stories, Support, Symptoms.

Font Size:

New Research Drugs in the Pipe ...

 This comprehensive list and presentations have been provided by board member "willing" and expanded here for easy viewing and is related to the timing of the new drugs coming to market and associated information which may help in making the dicision of when to start treatment.


Frontiers in Drug Development for Viral Hepatitis

Selected Slide Presentations

Click on the links below to view presentations


Satellite Mini-Symposium: Toward Curative Therapies for Hepatitis C


IDX184 - A Novel, Liver-targeted, Once-a-day Nucleotide Prodrug for the Treatment of Chronic HCV Infection
Douglas Mayers; Idenix Pharmaceuticals, Inc., USA

Update on Nitazoxanide in the Treatment of Chronic Hepatitis C
Emmet Keeffe; The Romark Institute for Medical Research and Stanford University Medical Center, USA

Nucleosides: Resistance, Genotypes, and Combinations
David Nelson; University of Florida, USA

Global Burden of Hepatitis Viruses, Natural History and Management

State of the Art Presentation

The Future Burden of Chronic Liver Disease and Global Opportunities for Therapeutic Interventions
Brian McMahon; Alaska Native Medical Center and Alaska Native Tribal Health Consortium, USA

Magnitude of Hepatitis Infection in Egypt and Africa
Mostafa Mohamed; Ain Shams University, Egypt

Review of the HCC Epidemic
Hashem El-Serag; Baylor College of Medicine/Michael E. DeBakey VA Medical Center, USA

Hepatitis E: One Virus, Many Faces
Kenneth Sherman; University of Cincinnati College of Medicine, USA

Discoveries and Advances in HCV Basic Research

State of the Art Presentation

The Long and Winding Road Leading to the Discovery of HCV
Michael Houghton; Epiphany Biosciences, USA

Insights into NS5A: A New Emerging Drug Target
Timothy Tellinghuisen; The Scripps Research Institute, USA

New Targets I: Cellular Systems and Infectious Models

State of the Art Presentation

Understanding Stat-C by Using Cell Culture Models
Ralf Bartenschlager; University of Heidelberg, Germany

HCV Management: Looking into the Crystal Ball

HCV Treatment, Screening and Monitoring: 2009-2012
Jean-Michel Pawlotsky; Henri Mondor University Hospital, France

HCV Treatment, Screening and Monitoring: 2012-2015
David Nelson; University of Florida, USA

HCV Treatment, Screening and Monitoring: 2015 and Beyond
Adrian Di Bisceglie; Saint Louis University School of Medicine, USA

Emergence and Prevention of Viral Resistance

State of the Art Presentation

HBV Antiviral Drug Resistance: Prevention and Monitoring
Anna Lok; University of Michigan Medical Center, USA

An Update on HBV Resistance: The View From the Hepatocyte
Stephen Locarnini; VIDRL, Australia

Overview of HCV Resistance to Protease Inhibitors
Philippe Halfon; Hôpital Ambroise Paré, France

HCV Drug Resistance to Nucleoside and Non Nucleoside Polymerase Inhibitors: Potential Impact on HCV Therapies
Isabel Nájera; Roche Palo Alto, USA

A Retrospective Analysis of Tenofovir DF and Entecavir Combination Therapy in Patients with Chronic Hepatitis B (CHB) and Previous Treatment Failure (PTF)
Robert Gish; CPMC, USA

Clinical Trial Design

Lessons Learned from Failed/Negative Studies in HCV Drug Development
Paul Pockros; The Scripps Clinic, USA

Planning Clinical Trials in Acute Hepatitis C (HCV)
Douglas Dieterich; Mount Sinai School of Medicine, USA

Oral Abstract Presentations I

Selection of Hepatitis C Virus Resistant to Ribavirin
Dino Feigelstock; CBER, Food and Drug Administration, USA

Evidence that the Duck Hepatitis B Virus Covalently Closed Circular DNA is able to Survive Mitosis during Antiviral Therapy
Allison Jilbert; University of Adelaide, Australia

HCV Education Roundtable: Anticipating a New Clinical Paradigm for Hepatitis C Virus Treatment Overcoming Resistance

Anticipating a New Clinical Paradigm for Hepatitis C Virus Treatment: Overcoming Resistance
Veronica Miller; Forum for Collaborative HIV Research, USA

A New Perspective on Resistance:  Multiple Paths to SVR Resistance can be Overcome
Veronica Miller; Forum for Collaborative HIV Research, USA

New Targets II: Insights into Drug Mechanisms

Ribavirin - Still Needed, but How Does It Work?
Jordan Feld; Toronto Western Hospital Liver Centre, University of Toronto, Canada

Anti-HCV Mechanisms of Action of Cyclophilin Inhibitors
Philippe Gallay; The Scripps Research Institute, USA

Attacking HBV Assembly: a General Target and a Specific Solution
Adam Zlotnick; Indiana University, USA

Optimizing Outcome of Therapeutics for Hepatitis Infections

Can We Cure Hepatitis C without Interferon?
Yves Benhamou; Hôpital Pitié-Salpêtrière, France

Long Term Results of Pegylated Interferon Alfa 2a and Tenofovir for Hepatitis B
Patrick Marcellin; Hôpital Beaujon, France

The Case for Nucleosides as First Line Therapy for HBV Infection
Jules Dienstag; Massachusetts General Hospital, USA

Pharmacology and New Therapies for Hepatitis Infections

Ending the PEG Interferon/Ribavirin Era in HCV Therapy: The Importance of Multiple
Shots on Goal

Robert Schooley; University of California San Diego, USA

Pharmacology of IDX184, a Liver-targeted Nucleotide Prodrug for the Treatment of HCV
David Standring; Idenix Pharmaceuticals, Inc., USA

Oral Abstract Presentations II

The Discovery and Early Development of the HCV NS3 Protease Inhibitor BMS-605339
Fiona McPhee; Bristol-Myers Squibb, USA

Early Clinical Experience with BI201335, a Novel Hepatitis C Virus NS3-NS4A Serine Protease Inhibitor
Donald Jensen; University of Chicago Medical Center, USA

Assessment of Serum HCV-RNA at Week 12 Post-treatment is as Relevant as Week 24 to Predict SVR in HCV Patients Receiving Peginterferon plus Ribavirin
Michelle Martinot-Peignoux; INSERM U-773, Université Paris VII, France

Different Kinetics of Serum HBsAg Decline in HBeAg-positive vs HBeAg-negative Patients
during 3 Years of Telbivudine Treatment in Chronic Hepatitis B (CHB)

Karsten Wursthorn; Hannover Medical School, Germany

Co-infections, Therapeutic Modalities and Regulatory Issues

Public Health Challenges for HIV and Hepatitis C Coinfection
Gregory Dore; University of New South Wales, Australia

Treatment for Forgotten Population
Mark Sulkowski; Johns Hopkins University, USA

Regulatory Requirements for Combination Studies
Richard Robson; Christchurch Clinical Studies Trust, New Zealand

Immunological Approaches and Vaccines for Hepatitis Infections

HCV Persistence and IFN Resistance
Christoph Seeger; Fox Chase Cancer Center, USA

Oral Abstract Presentations

Efficacy, Safety, and Predictive Value of Early Virologic Response of albinterferon alfa-2b vs
peginterferon alfa-2a in Treatment-Naïve Patients With Genotype 1 Chronic Hepatitis C

Fred Poordad; Cedars-Sinai Medical Center, USA

Liver Damage, Decompensation Fibrosis and Hepatocellular Carcinoma

State of the Art Presentation

Prevention of HCC in Hepatitis B Patients Using Antiviral Agents
Yun-Fan Liaw; Chang Gung Memorial Hospital, Taiwan

Cellular Evolution in Patients Chronically Infected with Hepatitis B Virus
William Mason; Fox Chase Cancer Center, USA

Management of Liver "Stiffness" and Hepatocellular Carcinoma (HCC)
Masao Omata; University of Tokyo, Japan

Hepatic Elastography for Measuring Liver Fibrosis
Nezam Afdhal; Beth Israel Deaconess Medical Center, USA

Biomarkers of Liver Injury for Hepatitis Clinical Trials: An Overview of Longitudinal Studies
Thierry Poynard; Hôpital Pitié-Salpêtrière, France

Can an Aberrant IgG be used as a Biomarker for Disease Progression?
Timothy Block; Hepatitis B Foundation and Drexel University College of Medicine, USA

Oral Abstract Presentations III

MicroRNA: New Biomarkers in Chronic Liver Disease
Hans Peter Dienes; University Hospital Cologne, Germany

Late Breaker Oral Abstract Presentations

SPC3649 Antagonizes the HCV Host Factor MicroRNA-122 in Chronically Infected Chimpanzees and Suppresses HCV RNA Accumulation
Robert Lanford; Southwest Foundation for Biomedical Research, USA

A Phase Ib Placebo-Controlled, Randomized Study of the Safety, Pharmacokinetics and Antiviral Activity of p7 Inhibitor BIT225 in Patients with Hepatitis C Virus (HCV) Infection
Carolyn Luscombe; Biotron Limited, USA




Weight Tracker
Weight Tracker
Start Tracking Now
Start Date
Feb 03, 2010
by jepperone
Last Revision
Feb 03, 2010
by jepperone